Patent intelligence · US
US 2024390317
COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN
COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND…
Patent details — US 2024390317
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 28, 2024
- Expiration
- Nov 23, 2044
- Applicant
- BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]
- CPC classes
- A61K 31/ 351 A I, A61K 31/ 501 A I, A61K 31/ 4184 A I, A61K/31351
Quick answer
US 2024390317 (COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN) is held by BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]. Status: granted. Granted Nov 28, 2024. Expires Nov 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 351 A I, A61K 31/ 501 A I, A61K 31/ 4184 A I, A61K/31351, A61K/31382, A61K/314184
More from BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
MX 2025012909
METHOD FOR INDUCING AN IMMUNE RESPONSE
granted -
WO 2025210141
SYSTÈME D'ADMINISTRATION UTILE POUR L'ADMINISTRATION TOPIQUE D'ARN
granted -
US 2025281584
ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS
granted -
AR 132581
COMPOSICIÓN INMUNÓGENA ÚTIL PARA LA AUTOADMINISTRACIÓN POR CERDOS
granted -
US 2025195525
ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS
granted -
WO 2025046413
VECTEURS DE VIA DE VMN ET LEURS UTILISATIONS
granted -
WO 2025046414
VECTEURS DE CDV VIA ET LEURS UTILISATIONS
granted -
US 2025064917
HVT AIV VECTORS AND USES THEREOF
granted
Frequently asked questions
What is US patent 2024390317?
US 2024390317 (COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN) is held by BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]. Status: granted. Granted Nov 28, 2024. Expires Nov 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2024390317?
BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 2024390317 expire?
Our index shows an expiration date of Nov 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.